All Terrain Financial Advisors LLC Sells 2,900 Shares of Abbott Laboratories (NYSE:ABT)

All Terrain Financial Advisors LLC trimmed its position in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 52.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,604 shares of the healthcare product maker's stock after selling 2,900 shares during the quarter. All Terrain Financial Advisors LLC's holdings in Abbott Laboratories were worth $295,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ABT. Redwood Park Advisors LLC purchased a new stake in Abbott Laboratories in the fourth quarter worth $25,000. Noble Wealth Management PBC bought a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $26,000. NewSquare Capital LLC lifted its stake in shares of Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock valued at $27,000 after buying an additional 105 shares in the last quarter. WealthTrak Capital Management LLC purchased a new position in Abbott Laboratories in the 4th quarter valued at approximately $28,000. Finally, Rialto Wealth Management LLC bought a new stake in Abbott Laboratories during the 4th quarter valued at $29,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Abbott Laboratories news, SVP Eric Shroff sold 562 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $77,651.54. Following the completion of the sale, the senior vice president now directly owns 31,970 shares in the company, valued at approximately $4,417,294.90. The trade was a 1.73 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Sally E. Blount sold 2,600 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $129.66, for a total value of $337,116.00. Following the sale, the director now owns 34,058 shares of the company's stock, valued at approximately $4,415,960.28. This trade represents a 7.09 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 95,278 shares of company stock valued at $12,745,859 over the last ninety days. 0.46% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

ABT has been the subject of several analyst reports. Raymond James raised their target price on Abbott Laboratories from $132.00 to $142.00 and gave the stock an "outperform" rating in a research note on Thursday, April 17th. Stifel Nicolaus raised their price target on shares of Abbott Laboratories from $135.00 to $145.00 and gave the company a "buy" rating in a report on Thursday, April 17th. Wells Fargo & Company upped their price target on shares of Abbott Laboratories from $136.00 to $147.00 and gave the stock an "overweight" rating in a report on Thursday, April 17th. Barclays raised their price target on Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a report on Thursday, April 17th. Finally, StockNews.com downgraded shares of Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Abbott Laboratories currently has a consensus rating of "Moderate Buy" and an average price target of $142.59.

Abbott Laboratories Stock Down 0.2 %

Abbott Laboratories stock traded down $0.30 during trading hours on Monday, hitting $132.52. 5,752,044 shares of the stock traded hands, compared to its average volume of 6,125,684. The firm's 50-day moving average price is $130.21 and its two-hundred day moving average price is $122.99. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32. The company has a market cap of $229.83 billion, a PE ratio of 17.32, a PEG ratio of 2.52 and a beta of 0.80. Abbott Laboratories has a one year low of $99.71 and a one year high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The firm had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.38 billion. On average, research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be paid a dividend of $0.59 per share. The ex-dividend date is Tuesday, April 15th. This represents a $2.36 annualized dividend and a yield of 1.78%. Abbott Laboratories's dividend payout ratio is 30.61%.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.